anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: biotechnology; dentistry.SUBSTANCE: method for restoring or inhibiting dental erosion, promoting dental remineralization and/or enhancing anti-carious effects of fluoride includes applying to a tooth an oral care composition containing hydrophobin-like protein (hereinafter – HLP), having a polypeptide sequence selected from SEQ ID NO: 20 or SEQ ID NO: 22, and an orally acceptable carrier. HLP is present in the composition in the amount from 0.01 to 3 wt. % of the total weight of the composition. The oral care composition contains HLP having a polypeptide sequence selected from SEQ ID NO: 20 or SEQ ID NO: 22, if necessary, the effective amount of fluoride and an orally acceptable carrier. HLP is present in the composition in the amount from 0.01 to 3 wt. % of the total weight of the composition.EFFECT: group of inventions is effective for restoring or mitigating effects of dental erosion, promoting dental remineralization and enhancing anti-carious effects of fluoride.11 cl, 1 dwg, 4 tbl, 4 ex
FIELD: biotechnology, vaccines. SUBSTANCE: method involves preparing nutrient medium containing Hottinger digest, liver extract, peptone, dried yeast extract, sodium chloride, potassium dihydrogen phosphate, sodium hydrogen phosphate, glucose, cattle normal serum, L-arginine, Tween-80 and distilled water. Prepared medium is subjected for cold filtration through plate filter, sowing material of the strain BP-2 is added and submerged culturing is carried out. After culturing termination protective medium of the following composition is added, vol.%: gelatin 4; peptone 15; sucrose 20, and phosphate-buffer solution - the rest. This method ensures to obtain necessary concentration of microorganisms without cultural fluid concentrating. Protective medium ensures to retain viability of cells of the strain BP-2 for 12 months. EFFECT: improved method of vaccine preparing. 3 cl, 3 tbl
Conventional long-term animal studies to evaluate the carcinogenic potential of epirubicin have not been conducted, but intravenous administration of a single 3.6 mg/kg epirubicin dose to female rats (about 0.2 times the maximum recommended human dose on a body surface area basis) approximately doubled the incidence of mammary tumors (primarily fibroadenomas) observed at 1 year. Administration of 0.5 mg/kg epirubicin intravenously to rats (about 0.025 times the maximum recommended human dose on a body surface area basis) every 3 weeks for ten doses increased the incidence of subcutaneous fibromas in males over an 18 month observation period. In addition, subcutaneous administration of 0.75 or 1 mg/kg/day (about 0.015 times the maximum recommended human dose on a body surface area basis) to newborn rats for 4 days on both the first and tenth day after birth for a total of eight doses increased the incidence of animals with tumors compared to controls during a 24-month observation period.

Epirubicin was mutagenic in vitro to bacteria (Ames test) either in the presence or absence of metabolic activation and to mammalian cells (HGPRT assay in V79 Chinese hamster lung fibroblasts) in the absence but not in the presence of metabolic activation. Epirubicin was clastogenic in vitro (chromosome aberrations in human lymphocytes) both in the presence and absence of metabolic activation and was also clastogenic in vivo (chromosome aberration in mouse bone marrow).

In fertility studies in rats, males were given epirubicin daily for 9 weeks and mated with females that were given epirubicin daily for 2 weeks prior to mating and through Day 7 of gestation. When 0.3 mg/kg/day (about 0.015 times the maximum recommended human single dose on a body surface area basis) was administered to both sexes, no pregnancies resulted. No effects on mating behavior or fertility were observed at 0.1 mg/kg/day, but male rats had atrophy of the testes and epididymis, and reduced spermatogenesis. The 0.1 mg/kg/day dose also caused embryolethality. An increased incidence of fetal growth retardation was observed in these studies at 0.03 mg/kg/day (about 0.0015 times the maximum recommended human single dose on a body surface area basis). Multiple daily doses of epirubicin to rabbits and dogs also caused atrophy of male reproductive organs. Single 20.5 and 12 mg/kg doses of intravenous epirubicin caused testicular atrophy in mice and rats, respectively (both approximately 0.5 times the maximum recommended human dose on a body surface area basis). A single dose of 16.7 mg/kg epirubicin caused uterine atrophy in rats.
The invention relates to a high-safety edible beauty mask and a preparation method thereof. The beauty mask contains following components including, by weight, 1-10% of proteins, 0.75-1.5% of polysaccharides, 0.1-0.25% of sodium hyaluronate, 20-25% of glycerol and the balance deionized water. All the raw materials in the mask are food-grade, are free of any toxic and side effect, are edible and have nutritional values. Indexes of microorganism, heavy metal and the like in the mask are in conformity with a national standard of food and cosmetic. By means of reasonable weight proportion of each component in the mask, the mask has soft and comfortable feel on skins in external application, can fit skins well, has efficacies of moisture-preserving, whitening and resisting irradiation, can enable skin to be more smooth, white and flexible and can achieve a skin-caring and beauty effect. In addition, the mask is very high in safety. Chemical stabilities of main materials in the mask are subjected to a test in a vacuum space station environment. A result shows that structure characteristics of the main materials have no significant change after spaceflight carrying.
OBJECTIVE: We investigated the utility of telehealth instruction versus mail-based written instruction in facilitating high-risk human papillomavirus (hrHPV) self-collection among post-menopausal patients compared with pre-menopausal patients, as well as the impact on acceptability and feasibility.
METHODS: We conducted a prospective, randomized study of people eligible for cervical cancer screening, stratified by menopausal status, to undergo standard written or telehealth-based instructions for hrHPV self-collection. English speaking individuals residing in Oregon, with a cervix, eligible for primary hrHPV testing, and with access to a video-capable device were included. Patients with prior hysterectomy, trachelectomy, diagnosis of cervical cancer, or pelvic radiation for gynecologic cancer were excluded. We compared preference for and opinions about self-collection and hrHPV test results, by randomization group and stratified by menopausal status using descriptive statistics.
RESULTS: Among 123 patients enrolled, 61 identified as post-menopausal with a median age of 57 years. While the majority of post-menopausal participants who received telehealth instructions found it helpful, only 6.1% considered telehealth instructions necessary to complete self-testing. There was no difference in opinion of telehealth by menopausal status. Overall, 88.5% of post-menopausal participants preferred self-collection to provider-collection. There were no significant differences between pre- and post-menopausal participants in terms of test preference, discomfort, ease of use, or perceptions of self-collection.
CONCLUSION: Telehealth instruction did not add significant value to patients participating in hrHPV self-collection, nor did it alter the acceptability of hrHPV-self collection among an English-speaking cohort. Compared with prior experiences with provider-collected screening, hrHPV self-collection was preferred by both pre- and post-menopausal participants. There were no significant differences in preference for provider- versus self-collection when stratified by menopausal status.
The purpose of this study is to evaluate the effectiveness of cholesterol/lovastatin versus lovastatin alone to treat porokeratosis. Our working hypothesis is that both topical cholesterol/lovastatin and lovastatin alone are helpful in treating patients with disseminated superficial actinic porokeratosis (DSAP). Potential subjects will be approached by their care team member to be made aware of the study at MUSC Dermatology clinics. Subsequently, members of the study team will approach their own patients to ask for participation in this study. Pertinent project information, risks, and time commitment will be relayed to subjects. If subjects show interest in participating, they will be given consent forms to either sign or bring home for consideration. If the patient is eligible for the study, he or she will be randomly assigned to one of two groups. They will have a 50/50 chance of being in either group. You will not make the choice to which group you are assigned. The two groups are Group A (cholesterol/lovastatin) and Group B (lovastatin only). The patient will not be informed of which group they are in and will not be informed of what their study medication is, allowing single-blinding. Researchers will not be masked. Initial enrollment will occur virtually. Enrolled subjects will be followed up at monthly intervals for three months via virtual check-in. At each visit, participants will undergo brief physical examination; additionally, clinical photographs of the lesion will be obtained. Photographs will be stored in the electronic medical record and stored in a departmental secure drive for further analysis of lesion features. At each visit the novel DSAP- General Assessment Scale and RAND36 QoL scale will be administered. Patients will be contacted via virtual check-in visits at weeks 4, 8, and 12. Patients will be asked about compliance and any adverse effects experienced. Participants will also be contacted by phone by study team member to assess for any adverse effects at weeks 2 and 6 of treatment. Compounded topical medication prescribed to subjects will be self-applied twice daily. These medications will be prepared by Tide Water Pharmacy Charleston, SC and Chemistry RX Philadelphia, PA. Chemistry Rx will ship the medications to the patients. They will be prepared so the study will remain single-blinded. The associated costs will not be covered by the research budget. Dermoscopic and clinical photographs will be subsequently analyzed for the presence of cornoid lamella. The team will record any additional dermoscopic or clinicals feature that may arise during the analyses. Frequency of dermoscopic and clinical features will be analyzed against clinical involution to find possible predictors.
Studies 1 through 5 included 40 weeks of post-treatment follow-up. In each study, CHANTIX-treated patients were more likely to maintain abstinence throughout the follow-up period than were patients treated with placebo (Figure 2, Table 8).

Study 6

This study assessed the effect of an additional 12 weeks of CHANTIX therapy on the likelihood of long-term abstinence. Patients in this study (N=1927) were treated with open-label CHANTIX 1 mg twice daily for 12 weeks. Patients who had stopped smoking for at least a week by Week 12 (N= 1210) were then randomized to double-blind treatment with CHANTIX (1 mg twice daily) or placebo for an additional 12 weeks and then followed for 28 weeks post-treatment.

The continuous abstinence rate from Week 13 through Week 24 was higher for patients continuing treatment with CHANTIX (70%) than for patients switching to placebo (50%). Superiority to placebo was also maintained during 28 weeks post-treatment follow-up (CHANTIX 54% versus placebo 39%).

In Figure 3 below, the x-axis represents the study week for each observation, allowing a comparison of groups at similar times after discontinuation of CHANTIX; post-CHANTIX follow-up begins at Week 13 for the placebo group and Week 25 for the CHANTIX group. The y-axis represents the percentage of patients who had been abstinent for the last week of CHANTIX treatment and remained abstinent at the given timepoint.
Although the spatial, cellular and molecular landscapes of resected pancreatic ductal adenocarcinoma (PDAC) are well documented, the characteristics of its metastatic ecology remain elusive. By applying spatially resolved transcriptomics to matched primary and metastatic PDAC samples, we discovered a conserved continuum of fibrotic, metabolic and immunosuppressive spatial ecotypes across anatomical regions. We observed spatial tumor microenvironment heterogeneity spanning beyond that previously appreciated in PDAC. Through comparative analysis, we show that the spatial ecotypes exhibit distinct enrichment between primary and metastatic sites, implying adaptability to the local environment for survival and progression. The invasive border ecotype exhibits both pro-tumorigenic and anti-tumorigenic cell-type enrichment, suggesting a potential immunotherapy target. The ecotype heterogeneity across patients emphasizes the need to map individual patient landscapes to develop personalized treatment strategies. Collectively, our findings provide critical insights into metastatic PDAC biology and serve as a valuable resource for future therapeutic exploration and molecular investigations.
The recommended dosage of RYSTIGGO is based on body weight, as shown below in Table 1.

Administer the recommended dosage as a subcutaneous infusion using an infusion pump at a rate of up to 20 mL/hour once weekly for 6 weeks. For detailed preparation and administration instructions, see Preparation and Administration Instructions (2.3). 

Administer subsequent treatment cycles based on clinical evaluation. The safety of initiating subsequent cycles sooner than 63 days from the start of the previous treatment cycle has not been established.

If a scheduled dose is missed, RYSTIGGO may be administered up to 4 days after the scheduled time point. Thereafter, resume the original dosing schedule until the treatment cycle is completed.
PROBLEM TO BE SOLVED: To obtain a process for producing a low-mol.-wt. cellulose ether having a high storage stability by irradiating a mixture comprising a high-mol.-wt. cellulose ether and a base with an accelerates electron beam.  
     SOLUTION: A mixture comprising a high-mol.-wt. cellulose ether and a base is irradiated with an accelerated electron beam. The cellulose ether used has a viscosity-average mol.wt. of 50,000-500,000 g/mol, pref. examples being methylcellulose, a nonionic or ionic mixed methylcellulose ether, hydroxyethylcellulose, or a nonionic or ionic mixed hydroxyethylcellulose ether. The base used is a water-sol. inorg. salt having a buffer action and is used in an amt. of 0.01-4 wt.% of the cellulose ether. A suitable radiation source is a continuous electron beam accelerator. 
     COPYRIGHT: (C)1996,JPO
This phase I double blind clinical trial will be used to plan future, larger clinical trials that would test how autologous cells from the peripheral nerve may help in the repair of damaged brain cells in Parkinson's Disease (PD) or Multiple System Atrophy (MSA) and slow the progression of the diseases. We will be judging the feasibility of implanting a participant's own cells from a nerve in the leg into the substantia nigra area of the brain. Patients eligible for participation will be at an earlier in stage of the disease with symptoms being less severe and therefore would not yet qualify for DBS. The LEAP trial is a study where the first participant will receive an implantation of the cells from their own sural nerve (a nerve near the ankle), into the substantia nigra on both sides of their brain. The 6 participants who follow, will be randomized to one of two arms. The 3 participants assigned to the experimental arm will receive the graft. The 3 participants assigned to the control arm will receive a sham surgical procedure, where the sural nerve will be biopsied, and bilateral scalp incisions will be made. Those who do not receive the cells initially may be eligible to undergo another surgery at the end of the study, after un-blinding has occurred, to receive the cell implants.
In order to solve the defects of the prior art, the invention provides a medicament for treating viral respiratory tract infection and pneumonia, which comprises the following components: main drugs and prescription drugs. The main drugs comprise: wild fructus Toosendan, herba Speranskiae Tuberculatae, lignum Cinnamomi Camphorae root, herba Melastomatis Dodecandri, herba Polygoni Caespitosi, herba Artemisiae Annuae, herba Verbenae, rhizoma Phragmitis, herba Medicaginis Cannabis, lalang grass rhizome, herba et Gemma Agrimoniae, and semen Setariae. The dispensing comprises: rhizoma Acori Graminei, radix Puerariae, folium Mori, radix asparagi, herba Begoniae Laciniatae, caulis Clematidis Armandii, flos Mangiferae Indicae, radix Stephaniae Tetrandrae, herba Paederiae, herba seu radix Cirsii Japonici, rhizoma Polygoni Cuspidati, caulis Lonicerae, and Prunellae Spica. The medicine has the effects of relieving exterior syndrome, lowering turbid pathogen, clearing pestilence and detoxifying. Is mainly used for treating the lung-defense syndrome caused by toxin attack. After a large number of trials, the medicine has definite curative effect, is safe and has no toxic or side effect, and has better curative effect on patients with pneumonia infected by the novel coronavirus.
The Intervention Composed of Aerobic Training and Non-Exercise Physical Activity (I-CAN) study will investigate the effects of aerobic exercise training and increasing the amount of physical activity outside of training (Non-EX PA) on waist circumference, weight, and other cardiovascular disease risk factors in a prospective pilot trial. The investigators will randomize sedentary (\<6,500 steps per day) obese adults with at least one additional cardiovascular risk factor (N= 45) to a: (1) structured aerobic exercise program with no intervention on Non-Ex PA (AERO group, N=15); (2) structured aerobic exercise program with the additional goal of increasing Non-EX PA (AERO-PA group, N=15), or (3) a non-exercise control group (CON, N=15) for 6 months. Exercise groups will participate in the same aerobic training program (50 to 75% VO2 max), designed to be consistent with public health recommendations of 150 minutes per week of moderate physical activity. Non-Ex PA in the AERO group will be tracked throughout the entire 6 month intervention with pedometers capable of counting steps, but not displaying them to the participant (blind mode capable). The AERO-PA group will progressively increase Non-Ex PA throughout intervention using pedometers (a progressive increase of 1,000 to 3,000 steps per day above baseline levels). The AERO-PA group will also participate in lifestyle counseling grounded in the principles of the behavioral change theories to determine/reinforce strategies to increase Non-Ex PA. The primary outcome measure will be change in waist circumference following the intervention. The results of this pilot study will be used to determine the efficacy/feasibility of the intervention, and power a larger trial as an R01 application.
Control group participants will consist of the person with diabetes (PWD) and their two support team members (STM). The PWD will receive regular medical care from their usual providers. They will also receive an introductory educational session and written materials on diabetes, the importance of its control, and diabetes self-care strategies, and a blood glucose and physical activity monitoring log. They will be invited for study visits at 3, 6, and 12 months to measure cholesterol, A1c (for those with diabetes), blood pressure, height, and weight measurement. PWDs and STMs in the control condition will receive generic health promotion information during in-person visits or by mail. They will receive follow-up messages by text to remind them about study related events.
The invention discloses a preparation method for stir-fried codonopsis pilosula decoction pieces with rice. The preparation method for the stir-fried codonopsis pilosula decoction pieces with rice includes the steps that fresh codonopsis pilosula is cleaned and then aired to be of a certain water content, the codonopsis pilosula is cut into slices and mixed with rice, the codonopsis pilosula is moistened through the rice and absorbs water, the mixture is heated in a microwave oven, dried and sieved, and then the stir-fried codonopsis pilosula decoction pieces with rice can be obtained. The preparation method for the stir-fried codonopsis pilosula decoction pieces with rice has the advantages that compared with an existing rice stir-frying process, the codonopsis pilosula medicinal materials do not need to be dried in advance or moistened with water when cut, so that the labor loss and the loss of effective constituents are greatly reduced; the fresh medical materials are cut when reaching the water content of 50%, thus, only a little fluid can flow out, and the medical materials can be easily cut. Meanwhile, the medical material slices make full contact with the rice before being stir-fried with the rice, on one hand, the rice will absorb water in the medical materials, and on the other hand, no water needs to be added in the stir-frying process. By means of the microwave drying method, the heating time is greatly shortened. The heating temperature and time are controllable in the drying process. The preparation method for the stir-fried codonopsis pilosula decoction pieces with rice largely reduces the operation steps, shortens the operation time, is more efficient and realizes quantitative control over the process.
The invention relates to a traditional Chinese medicine composition for improving a piglet anti-infection immunization function and a preparation method thereof. The traditional Chinese medicine composition comprises, by weight, 5-10 parts of herba houttuyniae, 5-10 parts of cortex phellodendri, 5-10 parts of isatis root, 5-15 parts of ash bark, 5-15 parts of polygonum viviparum, 5-15 parts of coptis root, 10-20 parts of radix astragali, 10-20 parts of Chinese angelica, 3-5 parts of buffalo horn concentrate powder, 10-20 parts of herba violae and 3-5 parts of licorice root. The traditional Chinese medicine composition for improving a piglet anti-infection immunization function comprises the pure natural Chinese herbal medicines, can treat piglet early-onset escherichia coli-caused disease and adjust piglet internal organ balance and immunity, is safe and eco-friendly, does not produce medicine residue and can still produce effects on strains having resistance to antibiotic. The traditional Chinese medicine composition has good oral absorbency. The preparation method has simple processes and is suitable for industrial production. The traditional Chinese medicine composition has the characteristics of use simpleness, convenience and speediness. Compared with other dosage forms, the traditional Chinese medicine composition is suitable for treating piglet early-onset escherichia coli-caused disease in a large-scale culture field.
Patients randomized to 12 weeks of twice weekly yoga sessions. The yoga exercises have been designed specifically for patients with IPF.
Yoga is an ancient Indian practice, dating back several thousand years, with objective of uniting mind, body, and spirit. In Western cultures, Hatha yoga is most commonly practiced, and generally includes a set of physical poses(asanas), breathing techniques(pranayama) and deep relaxation(savasana).Yoga has been shown to increase mobility, reduce pain, and improve quality of life in many diseases. However, there is no study examining the effects of yoga training in AS patients.Therefore, the aim of this study is to investigate the effects of yoga training in AS patients.

60 AS patients aged 20-60 years will be randomly assigned to yoga or control group. Home exercises will be taught to both groups, and a brochure with home exercises will be given. The yoga group will participate in a yoga class 3 days a week, during 8 weeks. The control group will not participate in a yoga class, only will do home exercises. Assessments will be done at baseline and after 8 weeks.